Key result
Myostatin antibody mRK35 increases muscle weight ~20% and enhances force in nemaline myopathy mice.
Why the study?
Nemaline myopathy causes muscle weakness and smallness with no approved treatments available, prompting exploration of myostatin inhibition to combat disease-associated muscle deficits.
Does myostatin inhibition with mRK35 improve muscle size and force in a mouse model of nemaline myopathy?
Population
Mouse model with compound heterozygous nebulin mutations and wild-type mice
Comparison
Weekly intraperitoneal injections of 10 mg/kg mRK35
Design
Preclinical animal study
Follow-up
From two weeks of age until four months of age
Authors
Loading...
Hypothesis-generating for myostatin inhibition in nemaline myopathy; clinical translation remains untested.
Does myostatin inhibition with mRK35 improve muscle size and force in a mouse model of nemaline myopathy?
Pharmacological inhibition of myostatin with mRK35 increases muscle size and force in a mouse model of nemaline myopathy, suggesting a potential therapeutic option.
Lindqvist et al. (2023) studied Nemaline myopathy. mRK35 (myostatin antibody) was evaluated on Muscle weight gain. In a mouse model of typical nemaline myopathy, weekly administration of the myostatin antibody mRK35 increased muscle weight by approximately 20% and enhanced absolute tetanic force.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: